

Serum Talin-1 (TLN-1) as a Biomarker for the Diagnosis of Hepatocellular Carcinoma in Liver Cirrhosis

A Thesis

*Submitted for Partial Fulfilment of Master Degree
in Internal Medicine and Gastroenterology*

By

Reham Adel Ali Abou Zein

M.B.B.ch

Under supervision

Prof.Dr.Osama Abo El Fotoh Elsayed

*Professor of Internal Medicine and Gastroenterology
Faculty of Medicine – Ain Shams University*

Prof. Dr. Enas Mahmoud Fouda

*Professor of Internal Medicine and Gastroenterology
Faculty of Medicine – Ain Shams University*

Dr. Ahmed Mohamed El Ghandour

*Lecturer of Internal Medicine and Gastroenterology
Faculty of Medicine – Ain Shams University*

*Faculty of Medicine
Ain Shams University*

2018

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالَ

سَبِّحْكَ لَا إِلَهَ إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**, the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound gratitude to **Prof. Dr. Osama Abo El Fotoh Elsayed**, Professor of Internal Medicine and Gastroenterology Faculty of Medicine – Ain Shams University for his keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*I am also delighted to express my deepest gratitude and thanks to **Prof. Dr. Enas Mahmoud Fouda**, Professor of Internal Medicine and Gastroenterology Faculty of Medicine – Ain Shams University, for her kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.*

*I am deeply thankful to **Dr. Ahmed Mohamed El Ghandour**, Lecturer of Internal Medicine and Gastroenterology Faculty of Medicine – Ain Shams University, for his great help, active participation and guidance.*

Reham Adel Ali Abou Zein

List of Contents

Title	Page No.
List of Tables	5
List of Figures	8
List of Abbreviations	14
Introduction	1
Aim of the Work.....	21
Review of Literature	
▪ Hepatocellular Carcinoma	22
▪ Talin-1.....	101
Subjects and Methods	127
Results	136
Discussion	187
Summary	195
Conclusion.....	198
Recommendations	199
References	200
Arabic Summary	—

List of Tables

Table No.	Title	Page No.
Table (1):	Okuda staging system for HCC:	74
Table (2):	TNM staging for hepatocellular cancer.....	75
Table (3):	Shows CLIP scoring system.....	76
Table (4):	Child-Pugh scoring system.	78
Table (5):	Shows Eastern Cooperative Oncology Group(ECOG) performance scale:	79
Table (6):	Statistical comparison of sex and age in control group and patients group:	136
Table (7):	Statistical comparison of liver function tests and the international normalized ratio(INR) in control group and patients group:	138
Table (8):	Statistical comparison of kidney functions (urea and creatinine) in control group and patients group:	142
Table (9):	Statistical comparison of hemoglobin, white blood cells and platelets in control group and patients group:	143
Table (10):	Statistical comparison of Alpha feto protein in control group and patients groups:	145
Table (11):	Statistical comparison of Talin-1 in control and patients groups:	146
Table (12):	Statistical comparison of sex and age in all studied groups(control group, group of cirrhosis without HCC and group of cirrhosis with HCC:	147
Table (13):	Statistical comparison of liver function tests and INR all studied groups (control group, group of cirrhosis without HCC and group of cirrhosis with HCC).	149
Table (14):	Statistical comparison of number and percentage of patients with HCC according to child-pugh scoring system.	155
Table (15):	Radiological findings regarding HCC group:	156

List of Tables cont...

Table No.	Title	Page No.
Table (16):	Statistical comparison of kidney function tests in all studied groups (control group, group of cirrhosis without HCC and group of cirrhosis with HCC).	158
Table (17):	Statistical comparison of hemoglobin, white blood cells and platelets in all studied groups(control group, group of cirrhosis without HCC and group of cirrhosis with HCC).....	159
Table (18):	Statistical comparison of Alpha fetoprotein (AFP) in all studied groups(control group, group of cirrhosis without HCC and group of cirrhosis with HCC).	162
Table (19):	Statistical comparison of Talin-1in all studied groups(control group, group of cirrhosis without HCC and group of cirrhosis with HCC).....	164
Table (20):	Correlation between Talin-1 level and different studied parameters in cirrhosis group and HCC groups:	165
Table (21):	Relation between Talin-1 level and different studied parameters in all patients (Sex, Anti HCV and HBsAg).	178
Table (22):	Relation between Talin-1 level and different studied parameters (Sex, Anti HCV and Hepatitis b surface antigen) in cirrhosis without HCC group.....	179
Table (23):	Relation between Talin-1 level and different studied parameters (Sex, Anti HCV and Hepatitis b surface antigen, tumor number, tumor size, portal vein invasion and ascites) in cirrhosis with HCC group.....	180

List of Tables cont...

Table No.	Title	Page No.
Table (24):	Sensitivity and specificity of serum Talin-1 and AFP regarding control group and patient group (Cirrhosis & HCC).....	182
Table (25):	Sensitivity and specificity of serum Talin-1 and AFP regarding control and cirrhosis with HCC groups	183
Table (26):	Sensitivity and specificity of serum Talin-1 and AFP regarding control and cirrhosis without HCC groups	184
Table (27):	Sensitivity and specificity of serum Talin-1 and AFP regarding cirrhosis with HCC and cirrhosis without HCC groups.....	185

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Regional variation in the estimated Age-standardized incidence rates of liver cancer.....	24
Figure (2):	Natural history and biological drivers of HCV-induced HCC development.....	32
Figure (3):	Risk factors for HCC and different pathways of pathogenesis	43
Figure (4):	Investigating a mass in a cirrhotic liver.....	48
Figure (5):	Arterial phase CT scan demonstrating enhancement of hepatocellular carcinoma.....	63
Figure (6):	Portal venous phase CT scan demonstrating washout of hepatocellular carcinoma.....	64
Figure (7):	Hepatocellular carcinoma at MRI.....	66
Figure (8):	AASLD Diagnostic Algorithm for Suspected HCC Identified on Ultrasound Abbreviations	69
Figure (9):	Diagnostic algorithm and recall policy of European Association for the Study of the Liver (EASL) guideline in 2012	71
Figure (10):	Updated BCLC staging system and treatment strategy, 2011.....	81
Figure (11):	Domain structure and binding partners of talin	102
Figure (12):	Showing Structure of talin monomer and the position of various ligand binding sites including the C-terminal actin-binding site(ABS)	104
Figure (13):	(A) Integrin activation. (B) Pull-push mechanism of talin activation.....	107
Figure (14):	Bidirectional signaling across integrins	112
Figure (15):	Model of talin mediated integrin crosstalk	114
Figure (16):	Talin activates integrins at focal adhesions	116

List of Figures (cont...)

Fig. No.	Title	Page No.
Figure (17):	Crosstalk between talin and kindlin in displacement model of integrin activation	117
Figure (18):	ECM-cell communication is dictated by focal-adhesion players.....	120
Figure (19):	Sex distribution in control and patients groups.	137
Figure (20):	Age distribution in control and patients groups.	137
Figure (21):	Showing ALT in control group and patients group.	139
Figure (22):	Box plot figure showing AST in control group and patients group.	139
Figure (23):	Showing ALP in control group and patients group.	140
Figure (24):	Showing Albumin in control group and patients group.	140
Figure (25):	Box plot figure showing Bilirubin in control group and patients group.	141
Figure (26):	Showing INR in control group and patients group.	141
Figure (27):	Showing hemoglobin in control group and patients group.	144
Figure (28):	Showing platelets in control group and patients group.	144
Figure (29):	Box plot figure showing alpha fetoprotein in control group and patients groups.	145
Figure (30):	Box plot figure showing Talin-1 in control group and patients group.	146
Figure (31):	Showing sex distribution in all studied groups(control group, group of cirrhosis without HCC and group of cirrhosis with HCC)	148

List of Figures (cont...)

Fig. No.	Title	Page No.
Figure (32):	Showing Age distribution in all studied groups (control group, group of cirrhosis without HCC and group of cirrhosis with HCC).	148
Figure (33):	Showing ALT in all studied groups(control group, group of cirrhosis without HCC and group of cirrhosis with HCC).	151
Figure (34):	Box plot figure showing AST in all studied groups(control group, group of cirrhosis without HCC and group of cirrhosis with HCC).	152
Figure (35):	Showing ALP in all studied groups(control group, group of cirrhosis without HCC and group of cirrhosis with HCC).	152
Figure (36):	Showing Albumin in all studied groups(control group, group of cirrhosis without HCC and group of cirrhosis with HCC).	153
Figure (37):	Box plot figure showing Bilirubin in all studied groups(control group, group of cirrhosis without HCC and group of cirrhosis with HCC).....	153
Figure (38):	Showing INR in all studied groups(control group, group of cirrhosis without HCC and group of cirrhosis with HCC).	154
Figure (39):	Showing number of patients with HCC according to child pugh scoring system.	155
Figure (40):	Showing focal lesions in HCC group.....	156
Figure (41):	Showing focal size in HCC group.	157
Figure (42):	Showing presence of ascites and portal vein invasion in HCC group.	157

List of Figures (cont...)

Fig. No.	Title	Page No.
Figure (43):	Showing hemoglobin in all studied groups (control group, group of cirrhosis without HCC and group of cirrhosis with HCC).	160
Figure (44):	Showing platelets in all studied groups (control group, group of cirrhosis without HCC and group of cirrhosis with HCC).	161
Figure (45):	Showing alphafetoprotein in all studied groups (control group, group of cirrhosis without HCC and group of cirrhosis with HCC).	162
Figure (46):	Showing Talin-1 in all studied groups (control group, group of cirrhosis without HCC and group of cirrhosis with HCC).	164
Figure (47):	Correlation between Talin-1 and ALT in all patients.....	167
Figure (48):	Correlation between Talin-1 and AST in all patients.....	167
Figure (49):	Correlation between Talin-1 and ALP in all patients.....	168
Figure (50):	Correlation between Talin-1 and Albumin in all patients.....	168
Figure (51):	Correlation between Talin-1 and Bilirubin in all patients.....	169
Figure (52):	Correlation between Talin-1 and INR in all patients.....	169
Figure (53):	Correlation between Talin-1 and Urea in all patients.....	170
Figure (54):	Correlation between Talin-1 and Platelets in all patients.....	170
Figure (55):	Correlation between Talin-1 and AFP in all patients.....	171

List of Figures (cont...)

Fig. No.	Title	Page No.
Figure (56):	Correlation between Talin-1 and ALT in cirrhosis patients without HCC.....	172
Figure (57):	Correlation between Talin-1 and AST in cirrhosis patients without HCC.....	172
Figure (58):	Correlation between Talin-1 and ALP in cirrhosis patients without HCC.....	173
Figure (59):	Correlation between Talin-1 and Albumin in cirrhosis patients without HCC.....	173
Figure (60):	Correlation between Talin-1 and Bilirubin in cirrhosis patients without HCC.....	174
Figure (61):	Correlation between Talin-1 and INR in cirrhosis patients without HCC.....	174
Figure (62):	Correlation between Talin-1 and Urea in cirrhosis patients without HCC.....	175
Figure (63):	Correlation between Talin-1 and Hemoglobin in cirrhosis patients without HCC.....	175
Figure (64):	Correlation between Talin-1 and WBCs in cirrhosis patients without HCC.....	176
Figure (65):	Correlation between Talin-1 and AFP in cirrhosis patients without HCC.....	176
Figure (66):	Correlation between Talin-1 and WBCs in cirrhosis patients with HCC.....	177
Figure (67):	Correlation between Talin-1 and AFP in cirrhosis patients with HCC.....	177
Figure (68):	Relation between Talin-1 and Portal vein invasion in cirrhosis patients with HCC.	181
Figure (69):	Relation between Talin-1 and Ascites in cirrhosis patients with HCC.....	181
Figure (70):	ROC curve for AFP and Talin-1 between control and cases groups.	182
Figure (71):	ROC curve for AFP and Talin-1 between control and cirrhosis with HCC groups.	183

List of Figures (cont...)

Fig. No.	Title	Page No.
Figure (72):	ROC curve for AFP and Talin-1 between control and cirrhosis without HCC groups.	184
Figure (73):	ROC curve for AFP and Talin-1 between cirrhosis with HCC and cirrhosis without HCC groups.	185

List of Abbreviations

Abb.	Full term
A1ATD	Alpha 1 antitrypsin deficiency
AASLD.....	American Association for the study of Liver Diseases
AFB1.....	Aflatoxin B1
AFP	Alpha fetoprotein
AFU	Alpha L fucosidase
AIH	Autoimmune Hepatitis
AJCC.....	American Joint Committee on Cancer
ALP	Alkalinephosphatase
ALT	Alanine aminotransferase
AR	Androgen receptor
AST	Aspartate aminotransferase
BCLC	Barcelona - Clinic Liver Cancer
BMI.....	Body mass index
CLD.....	Chronic liver disease
CLIP.....	Cancer liver Italian Program
CLT	Cadaveric liver transplantation
CT	Computed tomography
CTAP	CT arterial portography
CT-HA	CT during hepatic angrography
DAA	Direct-acting antiviral
DCP.....	Des-gamma-carboxyprothrombin
DDLT	Decreased donor liver transplantation
DKK-1.....	Dickkopf-1
DNA	Deoxyribonucleic acid
EASL	European Association for the Study of the Liver
ECM.....	Extracellular matrix
ECOG.....	Eastern Cooperative Oncology Group

List of Abbreviations (Cont...)

Abb.	Full term
EGF-R.....	Epidermal growth factor receptor
ELISA	Enzyme linked immune-sorbent assay
EUROHEP.....	European Concerted Action on Viral Hepatitis
FAK.....	Focal adhesion kinase
FERM	four point one protein, ezrin, radixin and moesin
FGF-R.....	Fibroblast growth factor receptor
GP73	Golgi protein 73
GPC3.....	Glypican-3
HBeAg.....	Hepatitis B e antigen
HBsAg.....	Hepatitis B surface antigen
HBV	Hepatitis B virus
HCC	Hepatocellular carcinoma
HCV	Hepatitis C virus
HDV	Hepatitis Delta virus
HGF	Hepatocyte growth factor
HGFR.....	Hepatocyte growth factor receptor
HH	Haemochromatosis
HIV	Human immunodeficiency virus
HLA	Human leukocyte antigen
HNF-1.....	Hepatocyte nuclear factor 1
IGF.....	Insulin-like growth factor
IL-6	Interleukin 6
INR	International normalized ratio
LCA.....	Lens culinaris agglutinin
LDLT	Living donor liver transplantation
LH.....	Laparoscopic hepatectomy
MDK	Midkine
MELD	Model for end stage liver disease